Concepedia

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

Alasdair Coles, Cary Twyman, Douglas L. Arnold, Jeffrey Cohen, Christian Confavreux, Edward Fox, Hans-Peter Hartung, Eva Havrdová, Krzysztof Selmaj, Howard L. Weiner,

The Lancet · 2012 · 1.2K citations · 28 references

DOIFull text

Open access

Concepts

References

28

Rating neurologic impairment in multiple sclerosis

John F. Kurtzke · Neurology · 1983 · 14.9K citations

, , +14

The Robust Inference for the Cox Proportional Hazards Model

D. Y. Lin, L. J. Wei · Journal of the American Statistical Association · 1989 · 2.5K citations

, , +16

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

Jeffrey A. Cohen, Frederik Barkhof, Hans‐Peter Hartung et al. · New England Journal of Medicine · 2010 · 2.2K citations · Full text

, , +15

Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis

Richard A. Rudick, William H. Stuart, Peter A. Calabresi et al. · New England Journal of Medicine · 2006 · 1.3K citations · Full text

, , +11

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

Jeffrey Cohen, Alasdair Coles, Douglas L. Arnold et al. · The Lancet · 2012 · 1.2K citations

, , +11